Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors

NCT03057145 is registered in ClinicalTrials.gov with Geoffrey Shapiro, MD, PhD as lead sponsor.

NCT NCT03057145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03057145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors
Lead sponsor
Geoffrey Shapiro, MD, PhD
Phase
Phase 1
Overall status
Completed
Start date
March 10, 2017
Completion date
June 9, 2021
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor